Atmo Biosciences – Monitoring gut health with an ingestible gas-sensing capsule
Australian digital health startup Atmo Biosciences is commercialising a
world-first, patented, ingestible gas-sensing capsule technology. The Atmo
gas capsule detects clinically important gaseous biomarkers at their source
as it passes through the gut and transmits the data wirelessly to the cloud
for aggregation and analysis.
Gut disorders are among the most common ailments in the world, affecting
one in five people, with many cases remaining undiagnosed or unresolved.
However, intestinal physiology has historically been a ‘black box’, with
clinicians forced to rely on indirect diagnostic measures and
trial-and-error to determine individual physiology, disease state and
response to therapy.
By directly and selectively detecting the clinically important gaseous
biomarkers produced in the gut at the source of production, the Atmo
technology enables doctors to provide better targeted therapies to
manipulate the microbiome (such as diet or antibiotics).
This will help improve the management of common conditions such as
Irritable Bowel Syndrome and Inflammatory Bowel Disease, resulting in
earlier relief of symptoms and a better quality of life for millions of
sufferers, as well as healthcare cost savings.
Atmo CEO Mal Hebblewhite says the Atmo capsule has the potential to aid
gastrointestinal clinical practice and become a new gold standard for
monitoring gut wellness, dysfunction and disease.
Atmo licensed the technology in 2018 from RMIT University and Alfred
Health, where it was developed over nine years under the leadership of
Professor Kourosh Kalantar-zadeh and Professor Peter Gibson. The technology
underwent multiple animal trials and a first in-human trial, which
attracted enormous interest and publicity.
Atmo is using seed capital raised in 2019 to fund further development of
the capsule, as well as clinical trials to further de-risk the commercial
pathway and prepare for regulatory approval in the key export markets of
Europe and North America.
Find out more about Atmo Biosciences.